Summary by Moomoo AI
TransCode Therapeutics, Inc. (TransCode), a biopharmaceutical company, has filed a preliminary proxy statement with the SEC, indicating plans to propose amendments to its certificate of incorporation and its 2021 Stock Option and Incentive Plan at its upcoming 2024 Annual Meeting of Stockholders. The proposed amendments include authorizing a reverse stock split of common stock at a ratio ranging from 1-for-2 to 1-for-40, at the discretion of the Board, to comply with Nasdaq's minimum bid price requirement. Additionally, the company seeks to increase the number of shares available for issuance under its 2021 Stock Option and Incentive Plan by 3,000,000 shares. The Annual Meeting is scheduled for June 13, 2024, at the offices of Goodwin Procter LLP in Boston, MA. The proxy statement also covers the election of four directors, the ratification of the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and other business matters. The company will distribute the Proxy Statement for consideration in lieu of the Original Proxy Statement filed on April 29, 2024.
